Supprelin la implant
Products billed under this code include Supprelin LA implant.
Payment limit per 50 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Supprelin LA implant.
Payment limit per 50 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Supprelin LA implant | Endo USA, Inc. | 67979-0002-01 | 1 | $37,837.548 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $37,837.548 | +$345.574 | 50 MG | Supprelin la implant | v1, posted September 17, 2026 |
| 3Q26 | $37,491.974 | −$3,681.453 | 50 MG | Supprelin la implant | v1, posted September 15, 2026 |
| 2Q26 | $41,173.427 | −$2,011.912 | 50 MG | Supprelin la implant | v1, posted September 15, 2026 |
| 1Q26 | $43,185.339 | −$1,835.311 | 50 MG | Supprelin la implant | v1, posted September 15, 2026 |
| 4Q25 | $45,020.65 | −$539.741 | 50 MG | Supprelin la implant | v1, posted September 8, 2026 |
| 3Q25 | $45,560.391 | +$348.351 | 50 MG | Supprelin la implant | v1, posted March 10, 2026 |
| 2Q25 | $45,212.04 | −$49.756 | 50 MG | Supprelin la implant | v1, posted March 10, 2026 |
| 1Q25 | $45,261.796 | −$88.42 | 50 MG | Supprelin la implant | v1, posted December 19, 2025 |
| 4Q24 | $45,350.216 | +$1,191.963 | 50 MG | Supprelin la implant | v1, posted June 11, 2025 |
| 3Q24 | $44,158.253 | −$420.498 | 50 MG | Supprelin la implant | v1, posted June 11, 2025 |
| 2Q24 | $44,578.751 | +$2.816 | 50 MG | Supprelin la implant | v1, posted March 11, 2025 |
| 1Q24 | $44,575.935 | −$119.166 | 50 MG | Supprelin la implant | v1, posted December 19, 2024 |
| 4Q23 | $44,695.101 | +$1,425.083 | 50 MG | Supprelin la implant | v1, posted October 10, 2024 |
| 3Q23 | $43,270.018 | −$270.982 | 50 MG | Supprelin la implant | v1, posted June 5, 2024 |
| 2Q23 | $43,541.00 | +$216.397 | 50 MG | Supprelin la implant | v1, posted February 23, 2024 |
| 1Q23 | $43,324.603 | −$742.217 | 50 MG | Supprelin la implant | v1, posted December 6, 2023 |
| 4Q22 | $44,066.82 | +$1,764.239 | 50 MG | Supprelin la implant | v1, posted June 22, 2023 |
| 3Q22 | $42,302.581 | −$499.542 | 50 MG | Supprelin la implant | v1, posted June 9, 2023 |
| 2Q22 | $42,802.123 | −$640.203 | 50 MG | Supprelin la implant | v1, posted December 14, 2022 |
| 1Q22 | $43,442.326 | −$24.705 | 50 MG | Supprelin la implant | v1, posted June 8, 2022 |
| 4Q21 | $43,467.031 | +$1,821.484 | 50 MG | Supprelin la implant | v1, posted June 2, 2022 |
| 3Q21 | $41,645.547 | −$127.585 | 50 MG | Supprelin la implant | v1, posted June 2, 2022 |
| 2Q21 | $41,773.132 | +$1,657.13 | 50 MG | Supprelin la implant | v1, posted March 1, 2022 |
| 1Q21 | $40,116.002 | – | 50 MG | Supprelin la implant | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.